

# **Evaluation of influenza vaccine effectiveness**

*A guide to the design and interpretation of  
observational studies*

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**

---

## Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies

ISBN 978-92-4-151212-1

© World Health Organization 2017

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO); <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>.

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Evaluation of influenza vaccine effectiveness: a guide to the design and interpretation of observational studies. Geneva: World Health Organization; 2017.

Licence: CC BY-NC-SA 3.0 IGO.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

Printed in Geneva, Switzerland

---

# **Evaluation of influenza vaccine effectiveness**

***A guide to the design and interpretation of  
observational studies***

**Immunization, Vaccines and Biologicals**



**World Health  
Organization**



---

# Contents

Acknowledgements .....	<i>ii</i>
Abbreviations & acronyms .....	<i>iii</i>
<b>1. Introduction</b> .....	<b>1</b>
1.1 Purpose of this guide and target audience .....	1
1.2 Epidemiology of influenza .....	2
1.3 Influenza vaccines .....	3
1.4 Organization of this guide .....	4
<b>2. The role of VE studies in influenza vaccination programmes</b> .....	<b>5</b>
2.1 Challenges to studying the impact of influenza vaccination programmes .....	6
2.2 Use of VE studies to estimate impact of influenza vaccination programmes .....	7
<b>3. Outcomes of interest for influenza VE studies</b> .....	<b>8</b>
<b>4. Assessing influenza vaccination history</b> .....	<b>15</b>
<b>5. Measuring covariates</b> .....	<b>18</b>
5.1 Key covariates .....	19
5.2 Other covariates .....	20
<b>6. Study designs</b> .....	<b>22</b>
6.1 Cohort studies .....	22
6.2 Case-control studies .....	24
6.3 The test-negative design: a special instance of case-control evaluation .....	25
6.4 The screening method .....	26
<b>7. Statistical considerations</b> .....	<b>27</b>
7.1 Sample size .....	27
7.2 Characterizing the study participants .....	28
7.3 Analytic approaches to estimate crude rate/odds ratios .....	28
7.4 Assessing potential confounders .....	29
7.5 Final analyses .....	29
7.6 Pooling data from multiple VE studies .....	29
<b>8. Building a test-negative study onto SARI surveillance</b> .....	<b>31</b>
8.1 SARI case definition .....	32
8.2 Laboratory testing .....	32
8.3 Timing of enrolment .....	33
8.4 Other considerations .....	33
<b>9. Reporting influenza VE results</b> .....	<b>34</b>
9.1 Description of influenza vaccines .....	34
9.2 Description of circulating influenza viruses .....	35
9.3 Stratification of VE estimates .....	35
References .....	36
Annex 1. Glossary of terms .....	46

---

---

# Acknowledgements

The preparation of this publication was coordinated by the Initiative for Vaccine Research of the WHO Department of Immunization, Vaccines, and Biologicals.

The lead writer was **Michael L. Jackson** of the Group Health Research Institute, Seattle, WA, USA. The document was initially discussed in a WHO expert consultation in February 2014. The following participants at this consultation provided document development advice and technical input during the writing process: **Alicia M. Fry** (Centers for Disease Control and Prevention, Atlanta, GA, USA), **Mark A. Katz** (Ben Gurion University of the Negev, Beer-Sheva, Israel), **Carlos Lara** (University of Antwerp, Antwerp, Belgium), **Danuta M. Skowronski** (British Columbia Centre for Disease Control, Vancouver, Canada), **Dipika Sur** (Consultant THSTI, Delhi, India), **John C. Victor** (PATH, Seattle, WA, USA), and **Syed M.A. Zaman** (Medical Research Council Unit, The Gambia).

Others provided helpful reviews and suggestions during the public comment period: ACOG Immunization Expert Work Group (American College of Obstetricians and Gynecologists, Washington, DC, USA), **Jon S. Abramson** (Wake Forest School of Medicine, Winston-Salem, NC, USA), **Ben Cowling** (The University of Hong Kong, Hong Kong SAR, China), **C. El Guerche Seblain** (Sanofi Pasteur, Lyon, France), **Nathalie El Omeiri** (Pan American Health Organization/World Health Organization, Washington DC, USA), **Jill M. Ferdinands** (Centers for Disease Control and Prevention, Atlanta, GA, USA), **Chuanxi Fu** (Guangzhou Center for Disease Control and Prevention, Guangzhou, China), **Alan R. Hinman** (Task Force for Global Health, Decatur, GA, USA), **Terri B. Hyde** (Centers for Disease Control and Prevention, Atlanta, GA, USA), **Peter B. McIntyre** (National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children's Hospital at Westmead and the University of Sydney, New South Wales, Australia), **Jozef J. P. Nauta** (Abbott EPD, Weesp, Netherlands), **Wilfred Ndifon** (African Institute for Mathematical Sciences, Cape Town, South Africa), **S. I. Samson** (Sanofi Pasteur, Lyon, France), **James A. Southern** (Advisor to Medicines Regulator, Simon's Town, South Africa), and **Sheena G. Sullivan** (WHO Collaborating Centre for Reference and Research on Influenza, Melbourne, Australia).

Technical coordination and input was provided by **Justin R. Ortiz** of the WHO Initiative for Vaccine Research. Additional technical review for WHO was provided by **Thomas Cherian**, **Adam L. Cohen**, **Joachim Hombach**, and **Ole Wichmann**.

WHO thanks the US Centers for Disease Control and Prevention for providing funds to the WHO Initiative for Vaccine Research which supported the production of this document.

---

# Abbreviations & acronyms

<b>ACIP</b>	Advisory Committee on Immunization Practices of the United States of America
<b>ARI</b>	Acute respiratory infection
<b>CDC</b>	Centers for Disease Control and Prevention of the United States of America
<b>COPD</b>	Chronic obstructive pulmonary disease
<b>EPI</b>	Expanded Programme on Immunization
<b>FluCAN</b>	Influenza Complications Alert Network in Australia
<b>GISRS</b>	WHO Global Influenza Surveillance and Response System
<b>HA</b>	Influenza hemagglutinin glycoprotein
<b>Hib</b>	Haemophilus influenzae type b
<b>IIV</b>	Inactivated influenza vaccine
<b>ILI</b>	Influenza-like illness
<b>I-MOVE</b>	Influenza Monitoring of Vaccine Effectiveness (I-MOVE) network in Europe
<b>ICU</b>	Intensive care unit
<b>IVR</b>	WHO Initiative for Vaccine Research
<b>NA</b>	Influenza neuraminidase glycoprotein
<b>PCV</b>	Pneumococcal conjugate vaccine
<b>RCT</b>	Randomized clinical trial
<b>REVELAC-I</b>	Multicentre network for evaluation of influenza vaccine effectiveness in Latin America
<b>RT-PCR</b>	Reverse transcription-polymerase chain reaction
<b>SARI</b>	Severe acute respiratory infection
<b>SPSN</b>	Canadian Sentinel Practitioner Surveillance Network
<b>STROBE</b>	Strengthening the Reporting of Observational Studies in Epidemiology
<b>VE</b>	Vaccine effectiveness
<b>WHO</b>	World Health Organization

预览已结束，完整报告链接和二维码如下：

[https://www.yunbaogao.cn/report/index/report?reportId=5\\_26548](https://www.yunbaogao.cn/report/index/report?reportId=5_26548)

